RxDoctor Payments Data

William Ennis

Surgical · Salisbury, MDNPI 1407199706

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Among surgical clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,461in general payments, 2019–2025

Across 125 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$449
  • Lilly USA, LLC$311
  • Pfizer$243
  • AstraZeneca$178
  • Amgen$152
  • Exact Sciences$116
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,461100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,461 in reported general payments places this provider in the 90th percentile of 277 surgical providers in Maryland.

See all surgical providers in Maryland

Medicare billing

Part B allowed, 2024
$228,650
Medicare patients
566
Services billed
2,520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$27,421
JanuviaSitagliptin Phosphate17$9,704
EliquisApixaban12$8,326
Febuxostat16$3,633
Lurasidone Hcl14$1,583
Pregabalin13$1,053
Cefdinir53$959
Albuterol Sulfate HfaAlbuterol Sulfate28$758
Lubiprostone15$549
Nystatin20$526
Levetiracetam35$514
Albuterol Sulfate18$502
Doxycycline Hyclate76$498
Tramadol Hcl68$475
Atorvastatin Calcium52$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$89$27,42129 claims
PfizerEliquis$243$8,32612 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$20$32344 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 277 surgical providers in Maryland.

Other surgical in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →